SHARES in ReNeuron, the life sciences firm that is using Glasgow’s Southern General Hospital for the world’s first stem clinical cell trial for a stroke treatment, dipped yesterday despite it unveiling positive pre-clinical data.
The Aim-quoted firm told the International Society for Extracellular Vesicles in Boston that there was evidence its flagship CTX stem cells produce “exosomes”, a type of particle that can help to stimulate tissues – such as blood vessels and neurons in the brain – to repair themselves.
Chief scientific officer John Sinden said: “The data we are presenting is exciting, both scientifically and commercially. The results provide further knowledge and validation of the therapeutic potential of our lead CTX cell therapy candidate.”
ReNeuron announced last month that it will use Ninewells Hospital in Dundee to see if stem cells can help restore the flow of blood to patients’ legs.